Skip to main content

Gout

National cohort of 20–39-yr old men - among ~1.3 million, 18,473 Dx w/ gout (incidence 3.36/1,000 PY). Developing metabolic syndr doubled #gout risk (aHR 2.31); MetS at all visits had 4x risk (aHR 3.82) & MetS recovery reduced gout risk by 59% https://t.co/bLmf1AL5VI https://t.co/8c47zk6vqu
Retrospective study of US National Inpatient Sample data 2015-2019 looked at 60,360 gout admissions, roughly 1/4 had Arrhythmias (mostly older pts; AFib (88%), atr flutter (6.2%), VTach (3.2%). Gout-arrhythmia pts had more deaths (adj OR 2.06) https://t.co/L1WEsybI7h https://t.co/xwAfFVJOuk
Methotrexate + pegloticase increases response rates in gout Patients with refractory gout and those with high burden of tophi have only few options when it comes to uric acid lowering agents. https://t.co/8cqsAXuzIB https://t.co/OSpf5ehiCm
COVID.virus_.corona.jpg (keep)

Rheum Drugs & IDSA Guidelines to Treat COVID-19

Dec 01, 2022

The Infectious Diseases Society of America has recently updated its recommendations with regards to the treatment of severely ill, hospitalized COVID-19 infected patients and also about the appropriate use of anti-IL-6, JAKs and colchicine.

Read Article
gout.MTP_.jpg

Methotrexate + pegloticase increases response rates in gout

In abstract 0001 presented at ACR22 Convergence, researchers presented 12-month data from a randomized double-blind placebo-controlled trial of pegloticase with or without MTX.

Read Article
GWAS analysis of 2.5m people (120k with gout) showing identifies 1486 candidate causal genes for gout. Looking at urate handling as well as disease propagation (eg. IL1/6). Widespread GWAS allowing us to investigate these diseases differently. @RheumNow #ACR22 #Plenary
#ACR highlights - #pegloticase in #gout - less reactions and more benefit w #MTX MIRROR RCT. Better than no MTX. Will change my practice - if I can access to a #peguricase, I will Rx w concomitant MTX Abst#0001 #ACR22 @RheumNow
Venuturupalli et al. Elevated CASPASE 1 expression in synovial biopsies of inter-critical gout suggest ongoing NLRP3 inflammasome activity between gout attacks. @RheumNow #ACR22 Abstr#1808 https://t.co/OnJOpkRqH9 https://t.co/TGd6pn8Lne
Nair et al. HLA-B*5801 allele in African American gout patients. Present in 8%. Higher than expected, ?need for screening pre-allopurinol? @RheumNow #ACR22 Abstr#1793 https://t.co/KrsjQ836BY https://t.co/bmPyqQi7OF
Hayashi et al. No effect of colchicine prophylaxis (vs NSAID or vs no prophylaxis) on MACE in re-analysis of CARES trial. @RheumNow #ACR22 Abstr#1809 https://t.co/I6evAl4BLd https://t.co/n70FvYah1p
Gurwith et al ABP-671 a URAT1 inhibitor effectively lowers serum urate @RheumNow #ACR22 Abstr#1822 https://t.co/hXAQoVHrLH https://t.co/saVqu4kbnr
Lin et al. Genetic risk (HR 2.3 women, 2.63 men) and lifestyle (HR 5.7 for women, 3.7 for men) both individual contributors and synergistic (HR 9.1 women, 8.7 men) in gout development in both men and women. Modifiable! @RheumNow #ACR22 Abstr#1633 https://t.co/51KPgfXn1w https://t.co/gOU7DfOKvt
Helget et al. Subanalysis of STOP Gout. Allopurinol and febuxostat equal efficacy in CKD 3. More AKI with allopurinol 8.3% vs 2.4%. @RheumNow #ACR22 Abstr#1829 https://t.co/Z4JqYp4mTT https://t.co/xd8VGJVkNo
Khanna et al Transdermal NaHCO₃ in gout flare. N=98. Response rate D7 95% vs 79% (p=0.01). Lower rescue med, 6% vs 20%. @RheumNow #ACR22 Abstr#1787 https://t.co/DWtlvjzBHw https://t.co/DOk993gCwz
Ho et al. Consistent colchicine use assoc reduction in MACE in patients with gout and pre-existing CVD. @RheumNow #ACR22 Abstr#1815 https://t.co/tXwa2FrSrp https://t.co/8TKl4z7iaH
Flood @FloodRachael et al. ULT reduces non-episodic foot pain in hyperuricaemic patients who fail to meet gout classification criteria. Predicted by double counter or tophus on US. @RheumNow #ACR22 Abstr#1828 https://t.co/iOy0Vo5HVO https://t.co/vF98DFB7hJ
McCormick et al Fruit juice and other sugar-sweetened drinks increase gout flare in dose-dependent manner @RheumNow #ACR22 Abstr#1805 https://t.co/aGg5i5XyTK https://t.co/x8ChwASM6P
Johnson et al. VA matched cohort study. 560,000 gout patients, 5.4 million controls. Gout asoc with increased CV risk of 68% HF hospitalization, 25% HF-related death, 22% MACE. Poor SU control assoc CVD events. @RheumNow #ACR22 Abstr#1580 https://t.co/CBSMFRpg82 https://t.co/6IS3Cozjzs
Black et al. Treat to target in gout. Monthly rheumatologist review and urate titration vs 6-monthly. 89% vs 40% at target ≤0.30mmol/L (<5mg/dl). SU decrease 38% vs 18%. US features also improved. @RheumNow #ACR22 Abstr#1579 https://t.co/TvxWAtl83y
Data like this make us think even in the setting of a controlled clinical trial in #gout, non-white patients much less likely to achieve target serum urate! Black pts 70% less likely to reach target compared to whites! #ACR22 @RheumNow abst#1583 https://t.co/dYet7pk2l5
Protective effect of #allopurinol in gout Dose dependent reduction in risk of acute coronary syndrome in incident #Gout #ACR22 @RheumNow abst#1582 https://t.co/PrEtRwvLvm
Fukui et al. Association different alcoholic drinks and urate in Japan. Patients always ask about this. We should drink more sake it seems! @RheumNow #ACR22 Abstr#1206 https://t.co/En5pSMUNp7 https://t.co/c67r9fsHJT
acr_session2.jpeg

ACR 2022 - Day 1 Report

Nov 13, 2022

The masses have returned to ACR22, a live, face-to-face, and virtual, meeting that began Saturday in Philadelphia. There were hassles and glitches, yet the education and sessions were as you’d expect with many good presentations worth recapping.

Read Article
EULAR19.abstract.jpg (keep)

ACR Best Abstracts - Day 1

Nov 12, 2022

The RheumNow faculty reporters have been scouring the meeting and online presentations to find the best abstracts from ACR22. Here are some of their choice abstracts reported today on day 1 of ACR 2022 (#ACRbest).



 

Read Article
×